We observed that vismodegib, a clinically used smoothened inhibitor, attenuates liver cell apoptosis via downregulation of DR5 and also reduces macrophage-associated hepatic inflammation in a dietary mouse model of NASH. This evidence concerns the gene TNFRSF10B and metabolic dysfunction-associated steatohepatitis.